VirtualScreeningofMultitargetKinaseInhibitors
articles
Table3.DistributionofTop6ScaffoldsinDual-Inhibitorsof7Intra-PTKGroupKinaseCombinationsofEGFR,VEGFR,PDGFR,FGFR,SrcandLck,andNon-Dual-InhibitorsoftheConstituentKinases
percentageofinhibitorscontainingscaffold
kinasepair
datasets
A63.8(37/58)0.2(3/1316)20.3(126/622)54.9(39/71)0.1(1/1303)25.5(100/392)33.9(38/112)0.2(2/1262)18.2(136/748)27.9(17/61)0.7(8/1232)5.6(25/445)67.4(155/230)1.8(8/450)11.2(26/233)76.1(143/188)2.9(14/492)3.7(25/672)0(0/56)21.6(174/804)5.9(26/450)
B
C
D
E
F
EGFR-PDGFRdual-inhibitors
EGFRnon-dual-inhibitorsPDGFRnon-dual-inhibitors
EGFR-FGFRdual-inhibitors
EGFRnon-dual-inhibitorsFGFRnon-dual-inhibitors
EGFR-Srcdual-inhibitors
EGFRnon-dual-inhibitorsSrcnon-dual-inhibitors
VEGFR-Lckdual-inhibitors
VEGFRnon-dual-inhibitorsLcknon-dual-inhibitors
PDGFR-FGFRdual-inhibitors
PDGFRnon-dual-inhibitorsFGFRnon-dual-inhibitors
PDGFR-Srcdual-inhibitors
PDGFRnon-dual-inhibitorsSrcnon-dual-inhibitors
Src-Lckdual-inhibitors
Srcnon-dual-inhibitorsLcknon-dual-inhibitors0(0/58)0(0/58)1.7(1/58)8.6(5/58)0(0/58)6.3(83/1316)1.2(16/1316)7.7(101/1316)0(0/1316)0(0/1316)0(0/622)0(0/622)0(0/622)7.1(44/622)0(0/622)0(0/71)0(0/71)32.4(23/71)7.0(5/71)0(0/71)6.4(83/1303)1.2(16/1303)6.1(79/1303)0(0/1303)0(0/1303)0(0/392)0(0/392)2.3(9/392)10.0(39/392)0.3(1/392)25.9(29/112)19.6(22/112)4.5(5/112)2.7(3/112)0(0/112)4.3(54/1262)1.6(20/1262)7.7(97/1262)0.2(2/1262)0(0/1262)10.4(78/748)0.8(6/748)5.0(37/748)1.60(12/748)2.8(21/748)29.5(18/61)0(0/61)0(0/61)0(0/61)34.4(21/61)0.8(10/1232)0(0/1232)5.4(66/1232)4.7(58/1232)0(0/1232)10.3(46/445)0(0/445)1.6(7/445)0(0/445)1.6(7/445)0(0/230)0(0/230)0(0/230)17.8(41/230)0(0/230)0(0/450)0(0/450)0.2(1/450)1.8(8/450)0(0/450)0(0/233)0(0/233)13.7(32/233)1.3(3/233)0.4(1/233)0(0/188)0(0/188)0(0/188)6.9(13/188)0(0/188)0(0/492)0(0/492)0.2(1/492)7.3(36/492)0(0/492)15.9(107/672)1.9(13/672)6.3(42/672)0.3(2/672)3.1(21/672)57.1(32/56)0(0/56)1.8(1/56)1.8(1/56)37.5(21/56)9.3(75/804)1.6(13/804)5.1(41/804)1.9(15/804)0(0/804)7.8(35/450)0(0/450)1.3(6/450)0(0/450)2(9/450)
VirtualScreeningPerformanceofCombinatorial
SVMinSearchingKinaseDual-InhibitorsfromLargeLibraries.TheVSperformanceofC-SVMinidentifyingdual-inhibitorsofthe11kinasepairsissummarizedinTable4andfurthershowninFigure4.TheparametersofthedevelopedSVMclassi cationmodelsfortheevaluatedkinasesareintherangeofσ)0.5-0.8.Thedual-inhibitoryieldsare27.6%forEGFR-PDGFR,40.9%forEGFR-FGFR,26.8%forEGFR-Src,52.6%forVEGFR-Lck,33.9%forPDGFR-FGFR,38.3%forPDGFR-Src,48.2%forSrc-Lck,52.3%forCDK1-CDK2,49.0%forCDK1-GSK3,57.3%forCDK2-GSK3,and12.2%forCDK1-VEGFRrespectively.Theyieldsfortheintra-PTKgroupandintra-CMGCgroupkinasepairsarecomparabletotheexpected25%-49%yieldsofcombinationsofgoodVStoolswithindividualyieldsof50%-70%.Therefore,C-SVMshowreasonablygoodcapabilityinidentifyingmultitargetagentsforkinasepairswithinaproteinkinasegroupwithoutrequiringexplicitknowledgeofmultitargetagents.However,theyieldfortheinter-PTK-CMGCkinasegroupCDK1-VEGFRkinasepairisonly12.2%,whichissigni cantlylowerthanthosefortheintra-PTKgroupandintra-CMGCgroupkinasepairs.StructuralanalysisoftheinhibitorsofCDK1andVEGFRbindingsiteshasrevealedthatinhibitorsgenerallymakeextensivefavorablevanderWaalscontactsandseveralhydrogenbondswithLys33,Leu83andAsp86atthehingeregionofCDK1,andwithCys919,Asn923,Cys1045andAsp1046atthehingeregionofVEGFRrespectively,relativelysmallstructuralchangesmayeasilyreducetheoptimal ttothebindingsite,andsomedual-inhibitorsareabletobindtobothkinasesbecauseoftheir
structural exibilitytotoleratethedifferentbindingsitegeometryandtoformalternativehydrogenbonds.60Insomecases,dualselectivityofinhibitorsofinter-kinase-groupkinasepairsmayrequirestructural exibilityto tinahydrophobicpocketconservedinbothkinaseclasses.61Suchspecialstructuralfeaturesindual-inhibitorsofinterkinase-groupkinasepairsarenotnecessarilyneededandthusmaynotbefoundinnon-dual-inhibitorsofindividualkinasesusedinourtrainingdatasets,whichcouldlikelybeanimportantreasonforthereducedyieldofC-SVMinidentifyingCDK1-VEGFRdual-inhibitors.ThesmallernumberofknownCDK1-VEGFRdual-inhibitorsmayalsoaffecttheaccurateassessmentofVSoutcome.
TargetselectivitywastestedbyusingC-SVMtoscreenthe233-1,316non-dual-inhibitorsofthe11kinasepairs,whichmisidenti ed9.2%and14.3%ofthenon-dual-inhibitorsofthekinasepairasdual-inhibitorsforEGFR-PDGFR,10.1%and8.7%forEGFR-FGFR,12.9%and11.1%forEGFR-Src,6.6%and29.2%forVEGFR-Lck,15.6%and22.3%forPDGFR-FGFR,25.8%and11.6%for
(60)Kuo,G.H.;Wang,A.;Emanuel,S.;Deangelis,A.;Zhang,R.;
Connolly,P.J.;Murray,W.V.;Gruninger,R.H.;Sechler,J.;Fuentes-Pesquera,A.;Johnson,D.;Middleton,S.A.;Jolliffe,L.;Chen,X.Synthesisanddiscoveryofpyrazine-pyridinebiheteroarylasanovelseriesofpotentvascularendothelialgrowthfactorreceptor-2inhibitors.J.Med.Chem.2005,48(6),1886–900.(61)Apsel,B.;Blair,J.A.;Gonzalez,B.;Nazif,T.M.;Feldman,M.E.;
Aizenstein,B.;Hoffman,R.;Williams,R.L.;Shokat,K.M.;Knight,Z.A.Targetedpolypharmacology:discoveryofdualinhibitorsoftyrosineandphosphoinositidekinases.Nat.Chem.Biol.2008,4(11),691–9.
VOL.7,NO.5MOLECULARPHARMACEUTICS1553
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
Synthesis and Characterization of Pyrazoleanthrone Derivatives as Aurora A Kinase Inhibitors_生产/经营管理_经管营销_专业资料。Chem.Res.Chin.Univ.2013.29(6)...
热门文档